# BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)

> **NCT02008006** · PHASE2 · TERMINATED · sponsor: **Centre Leon Berard** · enrollment: 21 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** BeEAM

## Key facts

- **NCT ID:** NCT02008006
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-09
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-07-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Insufficient recruitment and unavailability of the treatment
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008006, "BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02008006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*